Although many people are still pessimistic, I am confident that the trend is bullish. Ups and downs will make many people lose money. Everyone will never make money outside their own cognition. It is better to wait patiently in the direction of their own cognition.Today's A-share shrinkage is too obvious. Don't expect to get out of the anti-package, and it is not allowed to do so now. Institutions will definitely exert their strength when the market is calm. Today is the slow cow that meets the above requirements, but when the mood is calm, the quantity will also come down. How to understand it?1. Now the market has returned to the human nature stage of opening higher and going lower, opening lower and going higher. I've been watching more emotional outbursts and higher prices, but it happened that the market was calmed down by smashing the market, and everyone was more pessimistic. When I felt that the low price was going to plummet, the main institutions stood up and pulled up.
Today, it is actually very consistent with the characteristics of institutional efforts, because chasing up and down is the characteristic of many retail investors, but institutions generally regard retail investors as their own opponents.An important signal! Is A-share shrinking and rising? Or continue to put up a lot?The main reason is that yesterday's mood was too high, and the organization just had to wait until it calmed down before doing more. Of course, there will be another understanding, that is, the unexpected benefits will make some institutions empty, so some institutions need to continue to collect chips.
Originality is not easy. After reading the praise, form a good habit, pay attention to me, and time will give you the truest answer.Originality is not easy. After reading the praise, form a good habit, pay attention to me, and time will give you the truest answer.The plates were those that opened higher yesterday, and they have been further repaired today. At the end of the year, don't always think about chasing the daily limit, low-level consumer medicine, and the industry's low valuation leader, holding it steadily in the cyclical direction.
Strategy guide
12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14